Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy (AIM-HIGH)

For years, raising “good” HDL cholesterol seemed like an obvious way to lower cardiovascular risk, and niacin raised it better than almost anything. AIM-HIGH was the trial built to prove the strategy worked. Instead, it helped end it.

The investigators added extended-release niacin to intensive statin therapy in 3,414 patients with established disease, low HDL, and high triglycerides. The drug did exactly what it was supposed to do to the lab values: HDL rose 25 percent, triglycerides fell, LDL dropped further. And yet, after three years, there was no reduction in cardiovascular events whatsoever — the curves were essentially identical — and the trial was stopped early for futility, with a worrisome numerical uptick in stroke.

The lesson reverberates through cardiology. Moving a biomarker in a favorable direction is not the same as helping the patient. The “HDL hypothesis” — that raising HDL would cut events — could not survive contact with a randomized trial, and AIM-HIGH was a decisive piece of why.

We rate the evidence very strong. It is a rigorous, NIH-sponsored randomized trial whose negative result was as informative as any positive one — a durable warning against treating numbers instead of people.